

North Central Cancer Treatment Group

N0572: A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Addendum 6 – January 11, 2008

Summary

The risk section of the consent form for CCI-779 has been updated in accordance with a Safety Attachment associated with the Investigator Brochure, Edition 11, dated February 2007.

Replacement pages are included. Please incorporate into the protocol and keep this addendum with your protocol.

Title page Updated to reflect the addition of Addendum 6 and revised NCI version date.

Appendices 1A, 1B, 1C - Consent Forms

The risks for CCI-779 have been updated as follows due to the receipt of a Safety Attachment associated with the Investigator Brochure Edition 11 dated February 2007:

Hair loss (alopecia) has moved from the “Rare but serious” category to the “Likely” category.